Role of liposomal anthracyclines in breast cancer

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Anthracyclines are among the most effective drugs for patients with breast cancer. Their use, however, has been limited by associated toxic effects, including myelosuppression, alopecia, nausea and vomiting, stomatitis, and most importantly, cardiotoxicity. Liposomal anthracyclines were developed to increase the therapeutic index of conventional anthracyclines by maintaining antitumor efficacy while improving the safety profile. There are currently two liposomal formulations available for treatment of advanced disease: a not pegylated liposomal doxorubicin and a pegylated liposomal doxorubicin. This review will focus on both liposomal formulations of doxorubicin which are approved in Europe and Canada for use in patients with metastatic breast cancer.

Original languageEnglish
JournalAnnals of Oncology
Volume18
Issue numberSUPPL. 6
DOIs
Publication statusPublished - Jun 2007

Fingerprint

Anthracyclines
Breast Neoplasms
Stomatitis
Poisons
Alopecia
Nausea
Canada
Vomiting
Safety
Therapeutics
Pharmaceutical Preparations
liposomal doxorubicin

Keywords

  • Breast cancer
  • Cardiotoxicity
  • Liposomal anthracyclines

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Role of liposomal anthracyclines in breast cancer. / Lorusso, V.; Manzione, L.; Silvestris, N.

In: Annals of Oncology, Vol. 18, No. SUPPL. 6, 06.2007.

Research output: Contribution to journalArticle

@article{8ed87571797842c6a8588cc3c945ae5e,
title = "Role of liposomal anthracyclines in breast cancer",
abstract = "Anthracyclines are among the most effective drugs for patients with breast cancer. Their use, however, has been limited by associated toxic effects, including myelosuppression, alopecia, nausea and vomiting, stomatitis, and most importantly, cardiotoxicity. Liposomal anthracyclines were developed to increase the therapeutic index of conventional anthracyclines by maintaining antitumor efficacy while improving the safety profile. There are currently two liposomal formulations available for treatment of advanced disease: a not pegylated liposomal doxorubicin and a pegylated liposomal doxorubicin. This review will focus on both liposomal formulations of doxorubicin which are approved in Europe and Canada for use in patients with metastatic breast cancer.",
keywords = "Breast cancer, Cardiotoxicity, Liposomal anthracyclines",
author = "V. Lorusso and L. Manzione and N. Silvestris",
year = "2007",
month = "6",
doi = "10.1093/annonc/mdm229",
language = "English",
volume = "18",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL. 6",

}

TY - JOUR

T1 - Role of liposomal anthracyclines in breast cancer

AU - Lorusso, V.

AU - Manzione, L.

AU - Silvestris, N.

PY - 2007/6

Y1 - 2007/6

N2 - Anthracyclines are among the most effective drugs for patients with breast cancer. Their use, however, has been limited by associated toxic effects, including myelosuppression, alopecia, nausea and vomiting, stomatitis, and most importantly, cardiotoxicity. Liposomal anthracyclines were developed to increase the therapeutic index of conventional anthracyclines by maintaining antitumor efficacy while improving the safety profile. There are currently two liposomal formulations available for treatment of advanced disease: a not pegylated liposomal doxorubicin and a pegylated liposomal doxorubicin. This review will focus on both liposomal formulations of doxorubicin which are approved in Europe and Canada for use in patients with metastatic breast cancer.

AB - Anthracyclines are among the most effective drugs for patients with breast cancer. Their use, however, has been limited by associated toxic effects, including myelosuppression, alopecia, nausea and vomiting, stomatitis, and most importantly, cardiotoxicity. Liposomal anthracyclines were developed to increase the therapeutic index of conventional anthracyclines by maintaining antitumor efficacy while improving the safety profile. There are currently two liposomal formulations available for treatment of advanced disease: a not pegylated liposomal doxorubicin and a pegylated liposomal doxorubicin. This review will focus on both liposomal formulations of doxorubicin which are approved in Europe and Canada for use in patients with metastatic breast cancer.

KW - Breast cancer

KW - Cardiotoxicity

KW - Liposomal anthracyclines

UR - http://www.scopus.com/inward/record.url?scp=35748950745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748950745&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdm229

DO - 10.1093/annonc/mdm229

M3 - Article

VL - 18

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 6

ER -